Skip to content

Study on the Impact of Glucose and Lipid Metabolism Indicators on Clinical Characteristics and Prognosis of Coronary Heart Disease Patients

Study on the Impact of Glucose and Lipid Metabolism Indicators on Clinical Characteristics and Prognosis of Coronary Heart Disease Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114696
Enrollment
Unknown
Registered
2025-12-16
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Exposed group:None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who have undergone coronary angiography and been clearly diagnosed with coronary heart disease; 2.Aged >=18 years; 3.Complete clinical data: including comprehensive baseline clinical information (such as gender, age, height, weight, etc.), records of glucose and lipid metabolism indicators, and coronary angiography results; 4.For inclusion in the microcirculation analysis sub-cohort, one of the following conditions must be met: concurrent assessment using QFR or AMR, or coronary angiography image quality meets the basic requirements for offline QFR or AMR reconstruction analysis;

Exclusion criteria

Exclusion criteria: 1.Admission due to non-coronary heart disease-related causes: such as simple valvular disease, cardiomyopathy, congenital heart disease, pulmonary embolism, and other non-coronary heart disease-related causes; 2.Presence of other severe systemic diseases: such as severe liver and kidney dysfunction, immune system diseases, etc. 3.Incomplete data or missing key variables: such as severely missing clinical data, glucose and lipid metabolism indicators, or coronary angiography data that cannot be supplemented or obtained; 4.Pregnant or breastfeeding women; 5.Patients who refuse to participate in the study;

Design outcomes

Primary

MeasureTime frame
MACE(Major Adverse Cardiovascular Events);

Secondary

MeasureTime frame
Cardiovascular mortality;Rate of non-fatal myocardial infarction;

Countries

China

Contacts

Public ContactLin Zhao

China-Japan Friendship Hospital

zszll1995@163.com+86 10 8420 5046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026